Human Applications of PCI

GMT has developed several specific treatment regiments for; HIV/AIDS, Leishmaniasis, Dengue, Malaria, Zika Virus, and Necrotizing Fasciitis (“flesh-eating bacteria.”) caused by; Group A Streptococcus (GAS) bacteria. The same type of bacteria that causes strep throat; which we also readily inactivate.

Also in development is a self contained miniature Irradiator (PCI-2) for use in remote areas.  This has piqued the interest of South America, the Caribbean Basin and European countries and their Department of Wilderness, Department of Mining and Department of Defense.  The costs in South America to indigenous diseases  is exorbitant to say the least.

GMT offers Developing Countries throughout the world the ability to decrease their current cost to treat a multitude of diseases like HIV/AIDS, HEP-C, Ebola; and others that are catastrophic in nature by 90% .  These diseases are a constant strain on Developing Countries Government Healthcare Budget and GMT offers the saving of millions of lives at 90% less than current costs.

We also have the collaboration and participation of more than 500 medical professionals from the US, Canada, Colombia, Brazil, Chile, Russia, Germany, Denmark, Dominican Republic, Mexico, Spain, Switzerland, South Africa, Liberia, Guinea, China and the resources of some of the best Physicists and engineers from twelve (12) countries.

All these professional are collaborating with us in our clinical trials and in the concurrent implementation of PCI in various countries for HIV/AIDS.  GMT clinical trials will provide GMT with worldwide certification to provide a safe, viable treatment modality for any pathogen be it a virus, bacteria, fungus or parasite, which may affect us. These scientists understand that our success assures everyone on the planet the hope of a treatment for any infectious disease.